Structure of 2305-79-5
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
| CAS No. : | 2305-79-5 |
| Formula : | C7H10N2 |
| M.W : | 122.17 |
| SMILES Code : | C12=C(NN=C2)CCCC1 |
| MDL No. : | MFCD00014565 |
| InChI Key : | GDSQTWDUCDSZEY-UHFFFAOYSA-N |
| Pubchem ID : | 75317 |
| GHS Pictogram: |
|
| Signal Word: | Warning |
| Hazard Statements: | H315-H319-H335 |
| Precautionary Statements: | P261-P305+P351+P338 |
| Num. heavy atoms | 9 |
| Num. arom. heavy atoms | 5 |
| Fraction Csp3 | 0.57 |
| Num. rotatable bonds | 0 |
| Num. H-bond acceptors | 1.0 |
| Num. H-bond donors | 1.0 |
| Molar Refractivity | 36.02 |
| TPSA ? Topological Polar Surface Area: Calculated from |
28.68 Ų |
| Log Po/w (iLOGP)? iLOGP: in-house physics-based method implemented from |
1.17 |
| Log Po/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by |
1.44 |
| Log Po/w (WLOGP)? WLOGP: Atomistic method implemented from |
1.29 |
| Log Po/w (MLOGP)? MLOGP: Topological method implemented from |
1.08 |
| Log Po/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by |
2.5 |
| Consensus Log Po/w? Consensus Log Po/w: Average of all five predictions |
1.49 |
| Log S (ESOL):? ESOL: Topological method implemented from |
-1.92 |
| Solubility | 1.48 mg/ml ; 0.0121 mol/l |
| Class? Solubility class: Log S scale |
Very soluble |
| Log S (Ali)? Ali: Topological method implemented from |
-1.65 |
| Solubility | 2.75 mg/ml ; 0.0225 mol/l |
| Class? Solubility class: Log S scale |
Very soluble |
| Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by |
-2.3 |
| Solubility | 0.617 mg/ml ; 0.00505 mol/l |
| Class? Solubility class: Log S scale |
Soluble |
| GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg |
High |
| BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg |
Yes |
| P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) |
No |
| CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) |
No |
| CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) |
No |
| CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) |
No |
| CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) |
No |
| CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) |
No |
| Log Kp (skin permeation)? Skin permeation: QSPR model implemented from |
-6.02 cm/s |
| Lipinski? Lipinski (Pfizer) filter: implemented from |
0.0 |
| Ghose? Ghose filter: implemented from |
None |
| Veber? Veber (GSK) filter: implemented from |
0.0 |
| Egan? Egan (Pharmacia) filter: implemented from |
0.0 |
| Muegge? Muegge (Bayer) filter: implemented from |
1.0 |
| Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat |
0.55 |
| PAINS? Pan Assay Interference Structures: implemented from |
0.0 alert |
| Brenk? Structural Alert: implemented from |
0.0 alert: heavy_metal |
| Leadlikeness? Leadlikeness: implemented from |
No; 1 violation:MW<1.0 |
| Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) |
2.07 |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| Examples of said aryl-fused and heteroaryl--fused systems are: 1,2,3,4-tetrahydronapthalene, ... 4,5,6,7-tetrahydrobenzo[d]oxazole, 4,5,6-trihydro-1-thia-2-azapentalene, 4,5,6,7-tetrahydrobenzo[d]thiazole, 4,5,6-trihydro-1,2-diazapentalene, 4,5,6,7-tetrahydrobenzo[d]pyrazole, 4,6-diazaindane and 5,6,7,8-tetrahydroquinazoline. | ||
| Suitable examples of said R5 may include 5,6-dihydro-1H,4H-cyclopenta[c]pyrazole, 5,6-dihydro-2H,4H-cyclopenta[c]pyrazole, 5,6-dihydro-3H,4H-cyclopenta[c]pyrazole, 4,5,6,7-tetrahydro-1H-indazole, 4,5,6,7-tetrahydro-2H-indazole, 4,5,6,7-tetrahydro-3H-indazole, | ||
| Examples of said aryl-fused and heteroaryl-fused systems are: ... 4,5,6-trihydro-1,2-diazapentalene, 4,5,6,7-tetrahydrobenzo[d]pyrazole, 4,6-diazaindane and ... |
[ 204394-69-4 ]
[ 2305-79-5 ]
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| EXAMPLE 171 4-(4,5,6,7-Tetrahydro-1H-indazolyl)-2-(3-pyridinyl)-6-trifluoromethylpyrimidine The title compound was prepared from 4-chloro-2-(3-pyridinyl)-6-trifluoromethyl-pyrimidine (76 mg, 0.293 mmol) and <strong>[2305-79-5]4,5,6,7-tetrahydroindazole</strong> (44 mg, 0.360 mmol) similar to Example 166 and was isolated as a white solid (25 mg, 0.072 mmol, 25% %). 1H NMR (CDCl3) 9.68 (d, J 1.2 Hz, 1H), 8.75 (m, 2H), 8.40 (s, 1H), 8.07 (s, 1H), 7.45 (ddd, J=1.2, 5.1, 9.0 Hz, 1H), 2.73 (m, 4H), 1.88 (m, 4H). |
| Yield | Reaction Conditions | Operation in experiment |
|---|---|---|
| 83% | With iodine; potassium hydroxide; In N,N-dimethyl-formamide; at 0 - 20℃; | To a suspension of <strong>[2305-79-5]4,5,6,7-tetrahydroindazole</strong> (700 mg, 5.7 mmol) and KOH (1.2 g, 21.5 mmol) in DMF (20 mL) was added I2 (2.9 g, 11.5 mmol) at 0 C., and the reaction was stirred overnight while warming to rt. The reaction mixture was diluted with sat. Na2S2O3, extracted with EtOAc (50 mL*3), washed with brine (50 mL), dried (MgSO4), and concentrated to give 1.2 g (83%) of the title compound as a yellow oil. 1H NMR (400 MHz, CDCl3): delta 1.73-1.84 (4H, m), 2.40 (2H, t, J=5.6 Hz), 2.54 (2H, t, J=6.0 Hz). |
| With iodine; silver sulfate; In ethanol; at 20℃; for 18h; | Scheme 3- Step 1; A solution of <strong>[2305-79-5]4,5,6,7-tetrahydroindazole</strong> (5.Ig), silver sulphate (17g) and iodine (14g) in ethanol (100ml) was stirred at room temperature for 18 hours then filtered and evaporated. The residue was triturated with DCM then columned in 1-4% MeOH:DCM to afford the desired iodotetrahydroindazole (4g). | |
| With iodine; potassium hydroxide; In N,N-dimethyl-formamide; | To a solution of pyrazole 1 in DMF, was added potassium hydroxide (2.0 eq). The reaction was briefly sonicated for 5 min to help dissolution. Iodine (1.25 eq) was then added and the reaction mixture was stirred until complete (using TLC and LC/MS analysis). Additional portion of iodine (ca. 0.25 eq) could be added to drive reaction to completion. Once completed, the reaction was diluted with water and quenched with saturated sodium thiosulfate. The resulting crude mixture was transferred to a separatory funnel and extracted two times with EtOAc. The organic portions were then combined, washed three times with water and one time with brine, dried (Na2S04), filtered, and concentrated. The crude material was purified using Si02 chromatography and an appropriate gradient (ethyl acetate/hexanes or DCM/methanol) to give compound 2, as a solid or liquid. l-(2-f uorobenzyl)-3-(pyrimidin-5-yl)-4,5,6,7-tetrahydro-lH- indazole1H NMR: delta 9.12 (s, 1H), 9.10 (s, 2H), 7.29 (m, 1H), 7.05 (m, 3H), 5.33 (s, 2H), 2.72 (app. t, 2H), 2.57 (app. t, 2H), 1.82 (m, 4H). MS: 309.3 (M+l) |
| With iodine; sodium methylate; In methanol; at 20℃; for 2h; | To a solution of <strong>[2305-79-5]4,5,6,7-tetrahydro-1H-indazole</strong>, (37-S1, 1.22g, 10.0mmol) in anhydrous methanol (25.0 ml), sodium methoxide (1.1g) was added followed by iodine (3.57g) in one portion. The mixture was stirred at room temperature for 2 hours before the volatiles were removed. The residue was mixed with ethyl acetate and filtered through a short pad of silica gel. The filtrate was concentrated and the resulting material (37-S2) was carried forward in the next step without further purification. |

[ 2305-79-5 ]
[ 2305-79-5 ]

A312056 [1309788-50-8]
3-Iodo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole
Similarity: 0.72

A410298 [157327-44-1]
4,5,6,7-Tetrahydro-1H-pyrazolo[4,3-c]pyridine dihydrochloride
Similarity: 0.70

A339907 [871726-74-8]
4,5,6,7-Tetrahydro-1H-pyrazolo[3,4-c]pyridine dihydrochloride
Similarity: 0.69

A163275 [792848-34-1]
Ethyl 4,5,6,7-tetrahydro-1H-indazole-5-carboxylate
Similarity: 0.68

A142862 [19078-57-0]
4,5,6,7-Tetrahydropyrazolo[1,5-a]pyridine
Similarity: 0.68